WuXi AppTec subsidiary to manufacture Iovance’s solid tumor TIL therapy in US

WuXi Ad­vanced Ther­a­pies (ATU) will man­u­fac­ture Io­vance’s re­cent­ly ap­proved Am­tagvi for ad­vanced melanoma, which was her­ald­ed as the first mod­ern cell ther­a­py to se­cure an ap­proval in sol­id tu­mors and al­so the first ap­proval for a tu­mor-in­fil­trat­ing lym­pho­cyte-based ther­a­py.

WuXi ATU — a cell and gene sub­sidiary of WuXi AppTec — will be the first third-par­ty man­u­fac­tur­er to pro­duce the in­di­vid­u­al­ized T cell ther­a­py for sol­id tu­mors for com­mer­cial use, the man­u­fac­tur­er not­ed. The prod­uct’s an­a­lyt­i­cal test­ing and man­u­fac­tur­ing will be at WuXi ATU’s site lo­cat­ed near Io­vance’s Cell Ther­a­py Cen­ter at Philadel­phia’s Navy Yard.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.